As the U.S. market navigates a period of volatility with investors closely monitoring new tariffs and economic indicators, opportunities for growth can still be found in less conventional areas. Penny stocks, despite their somewhat outdated moniker, remain a relevant investment area for those interested in smaller or newer companies that might offer surprising value. By focusing on penny stocks with strong financial foundations, investors may discover potential long-term opportunities that larger firms often overlook.
Top 10 Penny Stocks In The United States
| Name | Share Price | Market Cap | Rewards & Risks |
| Safe Bulkers (NYSE:SB) | $3.69 | $394.21M | ✅ 3 ⚠️ 3 View Analysis > |
| Tuya (NYSE:TUYA) | $3.03 | $1.89B | ✅ 3 ⚠️ 3 View Analysis > |
| Cango (NYSE:CANG) | $3.79 | $410.15M | ✅ 4 ⚠️ 1 View Analysis > |
| Kiora Pharmaceuticals (NasdaqCM:KPRX) | $3.01 | $9.24M | ✅ 4 ⚠️ 1 View Analysis > |
| Sensus Healthcare (NasdaqCM:SRTS) | $4.73 | $78.68M | ✅ 5 ⚠️ 3 View Analysis > |
| TETRA Technologies (NYSE:TTI) | $3.36 | $477.94M | ✅ 5 ⚠️ 2 View Analysis > |
| Imperial Petroleum (NasdaqCM:IMPP) | $2.45 | $75.22M | ✅ 3 ⚠️ 1 View Analysis > |
| BAB (OTCPK:BABB) | $0.81 | $6.1M | ✅ 2 ⚠️ 3 View Analysis > |
| QuantaSing Group (NasdaqGM:QSG) | $3.08 | $174.81M | ✅ 3 ⚠️ 2 View Analysis > |
| CBAK Energy Technology (NasdaqCM:CBAT) | $0.7971 | $71.07M | ✅ 4 ⚠️ 1 View Analysis > |
Click here to see the full list of 762 stocks from our US Penny Stocks screener.
We'll examine a selection from our screener results.
2seventy bio (NasdaqGS:TSVT)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: 2seventy bio, Inc. is a cell and gene therapy company dedicated to researching, developing, and commercializing cancer treatments in the United States, with a market cap of $259.07 million.
Operations: The company generates revenue from its biotechnology segment, amounting to $37.86 million.
Market Cap: $259.07M
2seventy bio, Inc., a cell and gene therapy company, has recently agreed to be acquired by Bristol Myers Squibb for approximately US$286 million. Despite its current unprofitability and decreased revenue from US$100.39 million to US$37.86 million over the past year, the acquisition offers an 88% premium on its recent share price, signaling potential value recognition in its cancer treatment pipeline. The company's short-term assets of US$187.3 million exceed liabilities but do not cover long-term liabilities of US$228.6 million. With no debt and reduced losses over five years, it remains volatile with insider selling noted recently.
- Get an in-depth perspective on 2seventy bio's performance by reading our balance sheet health report here.
- Assess 2seventy bio's future earnings estimates with our detailed growth reports.
Equity Commonwealth (NYSE:EQC)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Equity Commonwealth (NYSE: EQC) is a Chicago-based, internally managed and self-advised real estate investment trust (REIT) focused on commercial office properties in the United States, with a market cap of approximately $173.19 million.
Operations: The company generates revenue primarily from the ownership and operation of office properties, totaling $57.57 million.
Market Cap: $173.19M
Equity Commonwealth, a Chicago-based REIT, reported US$47.98 million in revenue for the ten months ending October 2024, with net income of US$31.65 million despite a significant one-off loss of US$58.6 million impacting its results. The company is debt-free and has not diluted shareholders recently, while its seasoned management and board boast over a decade of experience on average. Although earnings have declined by 59.2% annually over five years and recent growth remains negative, EQC's short-term assets significantly exceed liabilities, providing financial stability amidst low return on equity and reduced profit margins year-over-year.
- Jump into the full analysis health report here for a deeper understanding of Equity Commonwealth.
- Gain insights into Equity Commonwealth's historical outcomes by reviewing our past performance report.
DUKE Robotics (OTCPK:DUKR)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: DUKE Robotics Corp. is a robotics company operating in Israel and Europe with a market cap of $9.22 million.
Operations: The company generates revenue from its Industrial Automation & Controls segment, amounting to $0.11 million.
Market Cap: $9.22M
DUKE Robotics Corp., with a market cap of US$9.22 million, remains in the pre-revenue stage, generating only US$0.108 million in sales for 2024. Despite its unprofitability and high share price volatility, the company maintains sufficient cash runway exceeding one year and has improved its financial position by turning negative shareholder equity positive over five years. Recent strategic expansions include establishing Duke Robotics Greece to leverage opportunities within Greece's infrastructure sector, particularly through its IC Drone technology. The appointment of Alexandra Papaconstantinou as Managing Director underscores DUKE's commitment to strengthening international business relations and operational management in Europe.
- Navigate through the intricacies of DUKE Robotics with our comprehensive balance sheet health report here.
- Understand DUKE Robotics' track record by examining our performance history report.
Seize The Opportunity
- Take a closer look at our US Penny Stocks list of 762 companies by clicking here.
- Looking For Alternative Opportunities? The end of cancer? These 21 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Equity Commonwealth might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com